Urinary tract infections (UTIs) represent a significant global health burden, ranking as the second most prevalent infection after respiratory tract disorders, with an estimated 40– 50% of the female population experiencing at least one episode during their lifetime. While contemporary medicine offers a diverse range of pharmacological interventions, their utility is increasingly constrained by the emergence of multi-drug resistant (MDR) strains, significant side effects, high recurrence rates, and the economic burden of long- term therapy. In response to these challenges, the Ayurvedic corpus offers a rich repository of botanical interventions for the management of Mutrakrichchra (dysuria), a clinical entity that closely correlates with UTIs. The present study was designed to evaluate the safety and clinical efficacy of two specific Ayurvedic formulations— Gokshur Ksheerapaka1 and ShatavariKsheerapaka—aiming to identify a therapeutic agent Urinary tract infections (UTIs) represent a significant global health burden, ranking as the second most prevalent infection after respiratory tract disorders, with an estimated 40– 50% of the female population experiencing at least one episode during their lifetime. While contemporary medicine offers a diverse range of pharmacological interventions, their utility is increasingly constrained by the emergence of multi-drug resistant (MDR) strains, significant side effects, high recurrence rates, and the economic burden of long- term therapy. In response to these challenges, the Ayurvedic corpus offers a rich repository of botanical interventions for the management of Mutrakrichchra (dysuria), a clinical entity that closely correlates with UTIs. The present study was designed to evaluate the safety and clinical efficacy of two specific Ayurvedic formulations— Gokshur Ksheerapaka1 and ShatavariKsheerapaka—aiming to identify a therapeutic agent
Dr. Parag Narayan Deshmukh2 Dr. Tehreen Mohammed Tarique*1 (Sun,) studied this question.